Positive data sends Amplia Therapeutics nearly 50 per cent upBiotech Amplia Therapeutics (ASX:ATX) was one of this morning’s biggest winners after positive clinical data. The company has a drug fighting cancer, AMP945, that inhibits Focal Adhesion Kinase (FAK).To view media story please click here. Posted on June 2nd, 2021 . Updated on September 16th, 2021 by Amplia Therapeutics